Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 7, 2008

BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery

  • BioTrove says it inked a new, nonexclusive marketing agreement with OSI Pharmaceuticals to provide clients with a complete solution for lead compound discovery.

    Combining OSI Pharmaceuticals’ Integrated Lead Discovery Platform with BioTrove’s RapidFire™ mass spectrometry-based assay development, screening, and analysis services, the agreement will enable customers to pursue challenging drug targets in a highly accurate, efficient, and cost-effective manner, explains Albert A. Luderer, Ph.D., president and CEO, BioTrove.

    “The collaboration addresses a critical, unmet need for companies in the biopharmaceutical industry, especially those without access to compound libraries or screening infrastructure,” continues Dr. Luderer.

    “Our joint solution with OSI will enable increased research around novel targets for companies who may have crucial insights about disease progression, but do not specialize in large-scale high-throughput screening internally.”